UNSPSC 51124402: Cymarin

This classification denotes an anti-arrhythmia agent and cardiotonic agent with the molecular formula C30H44O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UK3LS8435E, chemically known as 5-beta-card-20(22)-enolide, 3-beta-(beta-d-cymarosyloxy)-5,14-dihydroxy-19-oxo- but more generally known as cymarin, which bears US NIH Compound Identifier 10504. World Health Organization schedules cymarin in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, CYMARIN remains US FDA's Preferred Term for this commodity.

SMILES: CC1C(C(CC(O1)OC2CCC3(C4CCC5(C(CCC5(C4CCC3(C2)O)O)C6=CC(=O)OC6)C)C=O)OC)O.

UNSPSC 51124402 Cymarin is a Commodity code for pharmaceutical products—specifically, emergency medications and generic pharmaceuticals that state and local governments procure for fire rescue departments, health agencies, and cooperative purchasing alliances. State and local buyers under this code are sourcing advanced life support medications such as epinephrine, labetalol, adenosine, and diltiazem, as well as broader generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesale channels. Issuing bodies include municipal fire departments (Tampa Fire Rescue via the City of Tampa Purchasing Department), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix reflects both single-jurisdiction procurement for emergency medical services and coordinated multi-state purchasing vehicles that aggregate demand across state and local members.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's IFB for Advanced Life Support Medications (Solicitation 26P00188, due April 8, 2026, estimated value $40,000) seeks four specific medication line items for Tampa Fire Rescue with nine-month expiration warranties, ten-day delivery windows, and one-year initial contract terms renewable for two additional years. The procurement includes a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount not to exceed $10,000. Texas Health and Human Services Commission issued an exploratory RFI (HHS0017013, April 3, 2026 response deadline) on direct-to-manufacturer prescription programs and capacity for self-insured group plans outside traditional pharmacy benefit managers and wholesalers, signaling early-stage market research. MMCAP's RFP for Generic Multi Source Pharmaceuticals and OTC Products (S1070000015802, due March 26, 2026) sought manufacturers to supply products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) across participating state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026. All solicitations require cGMP and FDA compliance, comprehensive insurance, and product availability confirmed by specific dates.